Pain Management & Opioids

Pain Management / Opioids

💊 Pain Management & Opioids

A PharmD reference for opioid selection, equianalgesic conversion, and safe prescribing in acute and chronic pain. Covers renal/hepatic dose adjustment, naloxone reversal dosing, and risk-mitigation strategies aligned with the CDC's 2022 clinical practice guideline.

Multimodal Analgesia First

Opioids are not first-line for most acute or chronic non-cancer pain. Multimodal analgesia, combining non-opioid agents with different mechanisms, reduces total opioid exposure and improves pain control.

Class	Examples	Role
Acetaminophen	—	Foundation of multimodal regimens; max 3–4 g/day (lower in hepatic impairment)
NSAIDs	Ibuprofen, ketorolac, celecoxib	Effective for inflammatory/nociceptive pain; caution in renal impairment, GI bleed risk, and cardiovascular risk with prolonged use
Gabapentinoids	Gabapentin, pregabalin	Neuropathic pain; also reduce postoperative opioid requirements. Sedation is additive with opioids
Local/regional anesthesia	Lidocaine patches, nerve blocks	Reduce systemic opioid need for localized pain
Ketamine (low-dose)	—	Adjunct for refractory acute or postoperative pain, especially in opioid-tolerant patients

Equianalgesic Dosing (Approximate Oral Morphine Equivalents)

Opioid	Oral	IV/SC	Notes
Morphine	30 mg	10 mg	Active metabolite (M6G) accumulates in renal impairment
Oxycodone	20 mg	—	No parenteral form in the US
Hydromorphone	7.5 mg	1.5 mg	No clinically significant active metabolite accumulation; useful in renal impairment
Hydrocodone	30 mg	—	Combination products limited by acetaminophen content
Codeine	200 mg	—	Prodrug, CYP2D6-dependent activation; unpredictable in poor or ultra-rapid metabolizers
Fentanyl (transdermal)	25 mcg/hr patch ≈ 50–100 mg/day oral morphine		Conversion is approximate; avoid in opioid-naive patients; 12–24h delay to onset and offset
Methadone	Highly variable, non-linear		Do not use standard equianalgesic ratios; specialist dosing only, see below

⚠ These conversions are approximate and intended to guide cross-titration, not exact dosing. Reduce the calculated dose by 25–50% when switching opioids to account for incomplete cross-tolerance, then reassess.

Methadone: A Special Case

Methadone's equianalgesic ratio to morphine is dose-dependent and increases as cumulative morphine dose rises, roughly 4:1 at low morphine doses up to >12:1 at high doses, the opposite pattern from most opioids. Its terminal half-life (8–59 hours, highly variable) is much longer than its analgesic duration, creating a real risk of delayed accumulation and respiratory depression days after a dose increase.

Methadone also prolongs QTc in a dose-dependent way. Obtain a baseline ECG before starting and recheck with dose changes, especially at doses >100 mg/day or with concurrent QTc-prolonging drugs. Conversions to and from methadone should generally involve a pain specialist or a clinical pharmacist experienced in methadone dosing.

Renal & Hepatic Adjustment

Opioid	Renal Impairment	Hepatic Impairment
Morphine	Avoid or use with caution; active metabolites (M6G, M3G) accumulate and can cause prolonged sedation/respiratory depression	Reduce dose, extend interval
Hydromorphone	Preferred; minimal active metabolite accumulation at usual doses	Reduce dose, extend interval
Fentanyl	Preferred; hepatically cleared, no active metabolites	Reduce dose with severe impairment
Oxycodone	Use caution; reduce dose/frequency	Reduce dose, extend interval
Meperidine	Avoid; normeperidine accumulates and causes neurotoxicity/seizures	Avoid
Tramadol	Reduce dose	Reduce dose; also lowers seizure threshold

Naloxone Reversal Dosing

Scenario	Dose	Notes
Suspected opioid overdose (community/EMS)	0.4–2 mg IV/IM/SC, or intranasal 4 mg; repeat q2–3min as needed	Titrate to adequate respiration, not full arousal, to avoid precipitating acute withdrawal
Postoperative/iatrogenic respiratory depression	Low-dose titration: 0.04–0.1 mg IV q2–3min	Prevents precipitating severe pain or withdrawal in opioid-tolerant patients
Long-acting or high-dose overdose (methadone, extended-release, fentanyl analogs)	Consider a continuous infusion at ~2/3 of the effective bolus dose per hour	Naloxone's half-life (30–90min) is shorter than many opioids; monitor for re-sedation

PharmD Clinical Pearls

💡 Co-prescribe naloxone when risk factors are present: MME ≥50 mg/day, concurrent benzodiazepine use, history of overdose or opioid use disorder, or significant renal/hepatic/pulmonary disease. The CDC's 2022 guideline frames this as routine, not exceptional.

💡 The FDA boxed warning against combining opioids and benzodiazepines reflects real, additive respiratory depression risk. When unavoidable, use the lowest effective dose of each and ensure naloxone access.

💡 Every patient on a standing opioid needs a bowel regimen (stimulant laxative ± osmotic agent). Opioid-induced constipation does not resolve with tolerance the way sedation and nausea often do.

💡 The CDC's 2022 guideline explicitly moved away from hard MME or duration thresholds. Individualize therapy, and avoid abrupt discontinuation or rapid tapering in patients on long-term opioids, which is associated with overdose and mental health crisis risk.

💡 Check the state PDMP before initiating or renewing opioid therapy, and periodically during long-term therapy, per most state requirements.

🎓

Reviewed by a licensed pharmacist

Reference content reviewed for clinical accuracy. This is not a substitute for institutional protocols or professional judgment.

← Back to Clinical Reference · Literature Archive →